Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment

ConditionsObesity Body Composition

Trial statusRecruiting

Trial phaseNot applicable

Trial typeInterventional

Biological sexAll

Age18-99

SponsorMassachusetts General Hospital

About this trial

The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years old at time of signing informed consent

Started treatment with incretin therapy (liraglutide, semaglutide, tirzepatide, or retatrutide) within the past 2 months or planning to start this treatment

Able to provide informed consent

Disqualifiers

Current pregnancy (positive urine hCG) or plans to become pregnant in the next 6 months

BMI <25 kg/m2 at the time of screening

Unable to participate in a regular physical exercise program

Implanted pacemaker

Trial design

Design model

Parallel

Treatments tested in this trial

Smartwatch activity and body composition monitor
Device
Participants will be provided a smartwatch to monitor their exercise and body composition
General guidance on recommended exercise
Behavioral
Participants will receive general guidance on recommended exercise

Treatment groups

100 Participants

are divided into 2 treatment groups

Group A: Smartwatch activity monitorExperimental treatment 2 interventions

Group B: Usual guidanceActive comparator 1 intervention